Biomed-Lublin to be listed on the regulated market

The Polish pharmaceutical company applied for admission to trading B, C, D and E ordinary bearer shares in the regulated market. The admission date in the motion is January 30, ISBnews reported. The company applied for withdrawing B, C, D and E ordinary bearer shares from the NewConnect market under the condition of approval of the shares on the main market. The Polish Financial Supervision Authority (KNF) has approved the prospectus already. Biomed-Lublin Serum and Vaccine Production Plant has been manufacturing medicinal products, medical devices and laboratory reagents since 1944. It debuted on the NewConnect in 2011.